Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125

1.

In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction.

Shima F, Yoshikawa Y, Ye M, Araki M, Matsumoto S, Liao J, Hu L, Sugimoto T, Ijiri Y, Takeda A, Nishiyama Y, Sato C, Muraoka S, Tamura A, Osoda T, Tsuda K, Miyakawa T, Fukunishi H, Shimada J, Kumasaka T, Yamamoto M, Kataoka T.

Proc Natl Acad Sci U S A. 2013 May 14;110(20):8182-7. doi: 10.1073/pnas.1217730110. Epub 2013 Apr 29.

PMID:
23630290
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Discovery of small-molecule Ras inhibitors that display antitumor activity by interfering with Ras·GTP-effector interaction.

Shima F, Yoshikawa Y, Matsumoto S, Kataoka T.

Enzymes. 2013;34 Pt. B:1-23. doi: 10.1016/B978-0-12-420146-0.00001-9. Epub 2013 Nov 7. Review.

PMID:
25034098
[PubMed - indexed for MEDLINE]
3.

A RasGTP-induced conformational change in C-RAF is essential for accurate molecular recognition.

Hibino K, Shibata T, Yanagida T, Sako Y.

Biophys J. 2009 Sep 2;97(5):1277-87. doi: 10.1016/j.bpj.2009.05.048.

PMID:
19720015
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

The role of autophagy in cytotoxicity induced by new oncogenic B-Raf inhibitor UI-152 in v-Ha-ras transformed fibroblasts.

Ahn JH, Ahn SK, Lee M.

Biochem Biophys Res Commun. 2012 Jan 13;417(2):857-63. doi: 10.1016/j.bbrc.2011.12.061. Epub 2011 Dec 21.

PMID:
22206679
[PubMed - indexed for MEDLINE]
5.

A distinct class of dominant negative Ras mutants: cytosolic GTP-bound Ras effector domain mutants that inhibit Ras signaling and transformation and enhance cell adhesion.

Fiordalisi JJ, Holly SP, Johnson RL 2nd, Parise LV, Cox AD.

J Biol Chem. 2002 Mar 29;277(13):10813-23. Epub 2002 Jan 17.

PMID:
11799108
[PubMed - indexed for MEDLINE]
Free Article
6.

Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.

End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C.

Cancer Res. 2001 Jan 1;61(1):131-7.

PMID:
11196150
[PubMed - indexed for MEDLINE]
Free Article
7.

Identification and characterization of rain, a novel Ras-interacting protein with a unique subcellular localization.

Mitin NY, Ramocki MB, Zullo AJ, Der CJ, Konieczny SF, Taparowsky EJ.

J Biol Chem. 2004 May 21;279(21):22353-61. Epub 2004 Mar 18.

PMID:
15031288
[PubMed - indexed for MEDLINE]
Free Article
8.

Novel RasGRF1-derived Tat-fused peptides inhibiting Ras-dependent proliferation and migration in mouse and human cancer cells.

Sacco E, Metalli D, Spinelli M, Manzoni R, Samalikova M, Grandori R, Morrione A, Traversa S, Alberghina L, Vanoni M.

Biotechnol Adv. 2012 Jan-Feb;30(1):233-43. doi: 10.1016/j.biotechadv.2011.05.011. Epub 2011 May 18.

PMID:
21620943
[PubMed - indexed for MEDLINE]
9.

Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.

Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE.

Cancer Res. 2001 Dec 15;61(24):8758-68.

PMID:
11751396
[PubMed - indexed for MEDLINE]
Free Article
10.

Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity.

Elad-Sfadia G, Haklai R, Balan E, Kloog Y.

J Biol Chem. 2004 Aug 13;279(33):34922-30. Epub 2004 Jun 17.

PMID:
15205467
[PubMed - indexed for MEDLINE]
Free Article
11.

First experimental identification of Ras-inhibitor binding interface using a water-soluble Ras ligand.

Palmioli A, Sacco E, Abraham S, Thomas CJ, Di Domizio A, De Gioia L, Gaponenko V, Vanoni M, Peri F.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4217-22. doi: 10.1016/j.bmcl.2009.05.107. Epub 2009 May 30.

PMID:
19515561
[PubMed - indexed for MEDLINE]
12.

Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity.

Maurer T, Garrenton LS, Oh A, Pitts K, Anderson DJ, Skelton NJ, Fauber BP, Pan B, Malek S, Stokoe D, Ludlam MJ, Bowman KK, Wu J, Giannetti AM, Starovasnik MA, Mellman I, Jackson PK, Rudolph J, Wang W, Fang G.

Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5299-304. doi: 10.1073/pnas.1116510109. Epub 2012 Mar 19.

PMID:
22431598
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.

Kiga M, Tanzawa F, Iwasaki S, Inaba F, Fujiwara K, Iwadare H, Echigo T, Nakamura Y, Shibata T, Suzuki K, Yasumatsu I, Nakayama A, Sasazawa Y, Tashiro E, Imoto M, Kurakata S.

Anticancer Drugs. 2012 Jan;23(1):119-30. doi: 10.1097/CAD.0b013e32834c6a33.

PMID:
22008853
[PubMed - indexed for MEDLINE]
14.

Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.

Leftheris K, Kline T, Vite GD, Cho YH, Bhide RS, Patel DV, Patel MM, Schmidt RJ, Weller HN, Andahazy ML, Carboni JM, Gullo-Brown JL, Lee FY, Ricca C, Rose WC, Yan N, Barbacid M, Hunt JT, Meyers CA, Seizinger BR, Zahler R, Manne V.

J Med Chem. 1996 Jan 5;39(1):224-36.

PMID:
8568812
[PubMed - indexed for MEDLINE]
15.

Inhibition of Ras/Raf interaction by anti-oncogenic mutants of neurofibromin, the neurofibromatosis type 1 (NF1) gene product, in cell-free systems.

Mori S, Satoh T, Koide H, Nakafuku M, Villafranca E, Kaziro Y.

J Biol Chem. 1995 Dec 1;270(48):28834-8.

PMID:
7499408
[PubMed - indexed for MEDLINE]
Free Article
16.

Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity.

Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, Sebti SM.

Oncogene. 2005 May 5;24(20):3236-45. Erratum in: Oncogene. 2008 Feb 21;27(9):1344.

PMID:
15735720
[PubMed - indexed for MEDLINE]
17.

Asperolide A, a marine-derived tetranorditerpenoid, induces G2/M arrest in human NCI-H460 lung carcinoma cells, is mediated by p53-p21 stabilization and modulated by Ras/Raf/MEK/ERK signaling pathway.

Lv C, Sun W, Sun H, Wei S, Chen R, Wang B, Huang C.

Mar Drugs. 2013 Jan 29;11(2):316-31. doi: 10.3390/md11020316.

PMID:
23434831
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

The P34G mutation reduces the transforming activity of K-Ras and N-Ras in NIH 3T3 cells but not of H-Ras.

Oliva JL, Zarich N, Martínez N, Jorge R, Castrillo A, Azañedo M, García-Vargas S, Gutiérrez-Eisman S, Juarranz A, Boscá L, Gutkind JS, Rojas JM.

J Biol Chem. 2004 Aug 6;279(32):33480-91. Epub 2004 Jun 4.

PMID:
15181015
[PubMed - indexed for MEDLINE]
Free Article
19.

p204 protein is a novel modulator of ras activity.

Ding B, Lengyel P.

J Biol Chem. 2008 Feb 29;283(9):5831-48. doi: 10.1074/jbc.M709680200. Epub 2007 Dec 28.

PMID:
18165224
[PubMed - indexed for MEDLINE]
Free Article
20.

Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.

Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo P, Ruvolo V, Evangelisti C, Martelli AM, McCubrey JA.

Leukemia. 2011 Jul;25(7):1080-94. doi: 10.1038/leu.2011.66. Epub 2011 Apr 15. Review.

PMID:
21494257
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk